The RENCA trial might be a good option.
I will mention this study because, even if it is in Arkansas, a bit more far away than your location zone, it uses two oral agents (two pills), so maybe not so many trips are required, it's for KRAS mutant CRC patients. One of the agents was experimental until two weeks ago, but got just FDA approved. Targeted agents, not immunotherapy.
*For KRAS mutant.
*Non measurable disease accepted in phase I.
*No immunotherapy but a combination of targeted agents (small molecules)
*Trametinib + Ribociclib (Mekinist, a MEK inhibitor, Oral + an inhibitor of cyclin D1/CDK4 and CDK6, Oral)
*In Phase I, admits patients with all metastatic KRAS-mutant *solid tumours* "who have failed at least one prior line of systemic antineoplastic therapy in the advanced setting without a standard of care treatment option available". Non measurable disease accepted;
*For Phase II, only KRAS mut CRC are accepted; phase II requires measurable disease.https://clinicaltrials.gov/ct2/show/NCT02703571
Ribociclib ( inhibitor of cyclin D1/CDK4 and CDK6, Oral; previously it was called LEE 011, now the commercial name is KIsqali, manufactured by Novartis) has been approved past week for breast cancer (https://www.fda.gov/Drugs/InformationOn ... 546438.htm
), so using is now would be off-label.